Impact of USP 661.2 on the Pharmaceutical Industry
The pharmaceutical and biotechnology sector is undergoing a key transformation driven by USP 661.2, which redefines safety requirements for plastic materials in contact with medicines.
Increasing regulatory demands, along with the rise of advanced therapies, have intensified the need to accurately assess compounds that may migrate from packaging and delivery systems into pharmaceutical products.
In this context, extractables and leachables (E&L) studies have become a strategic area. The global market is estimated to exceed $2.5 billion before 2030, with annual growth close to 15%.
What Are Extractables and Leachables?
Extractables are chemical compounds that can be released from materials under aggressive laboratory conditions (high temperatures, solvents, extended time periods).
These studies make it possible to identify all potential contaminants present in:
- Pharmaceutical packaging
- Closure systems
- Delivery devices
- Polymeric materials
Leachables, on the other hand, are the substances that actually migrate into the drug under normal storage or use conditions.
The distinction is critical:
- Extractables: potential risk
- Leachables: actual risk
USP 661.2 Requirements
USP 661.2 introduces a more stringent framework for evaluating plastic materials used in pharmaceutical packaging.
Key requirements include:
- Advanced chemical characterization of polymers
- Identification of organic and inorganic compounds
- Evaluation of additives, stabilizers, and degradation products
- Studies of interactions between materials and drugs
It also requires the use of advanced analytical techniques such as:
- High-performance liquid chromatography (HPLC)
- Mass spectrometry
- Thermal analysis
Impact of USP 661.2 in Spain and Europe
Although it is part of the United States Pharmacopeia, USP 661.2 has a strong impact in Spain and across Europe because many companies export to the U.S., regulatory agencies use USP as a reference, and it aligns with EMA quality expectations.
This forces pharmaceutical laboratories, packaging manufacturers, and medical device companies to adapt their processes to meet international standards.
Sector Growth in 2026
The year 2026 marks a turning point driven by:
- New regulatory requirements such as USP 661.2
- Growth of biological and advanced therapies
- Increasing drug complexity
Products such as monoclonal antibodies, gene therapies, and mRNA are particularly sensitive to chemical contaminants.
Impact on Packaging Manufacturers
Manufacturers of materials and packaging must comply with USP 661.2 requirements, which involves:
- Comprehensive extractables studies
- Toxicological evaluation
- Compatibility validation
This is driving:
- Development of purer materials
- Elimination of critical additives
- Greater quality control throughout the supply chain
Opportunities for Analytical Laboratories
USP 661.2 is creating significant opportunities for chemical analysis laboratories, regulatory consultancies, and research centers.
Additionally, digitalization enables the analysis of large volumes of data and the detection of compounds at ultra-low levels.
Frequently Asked Questions
- What is USP 661.2?
USP 661.2 is a regulation that establishes requirements for evaluating plastic materials used in pharmaceutical packaging, ensuring their safety when in contact with medicines. - What are extractables and leachables?
These are chemical compounds that can be released from materials. Extractables are identified in laboratory conditions, while leachables are those that actually migrate into the drug product. - What is the difference between extractables and leachables?
Extractables represent a potential risk detected under extreme conditions, whereas leachables reflect the actual risk under normal conditions of use. - Is USP 661.2 mandatory in Spain and Europe?
It is not mandatory, but many companies must comply with it if they export to the United States or operate under international regulatory standards.
